Indications with ≥5 evaluable patients and <50% MAGE-A4 positivity were ovarian carcinoma; other (excluding serous/high-grade carcinoma; n = 4/9; 44%); gastric cancer (n = 3/7; 43%); endometrial cancer (n = 2/5; 40%); synovial sarcoma (n = 2/6; 33%); pancreatic cancer (n = 5/16; 31%); bladder urothelial carcinoma (n = 2/9; 22%); melanoma (n = 1/5; 20%); colorectal cancer (n = 3/22; 14%); breast cancer (n = 2/15; 13%); sarcoma, diverse (n = 1/14; 7%); and renal cell carcinoma (n = 0/5; Table 1). This evidence concerns the gene MAGEA4 and renal cell carcinoma.